Stockreport

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial [Yahoo! Finance]

PLUS THERAPEUTICS, Inc.  (PSTV) 
PDF CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rhenium (Re186) obisbemeda Company summarized [Read more]